Physiological Study to Determine the Role of the Melanocortin-4 Receptor in Brain Activity in Women With Hypoactive Sexual Desire Disorder
Phase: PHASE4
Conditions: Hypoactive Sexual Desire Disorder
Sponsor: Imperial College Healthcare NHS Trust

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
1 
 
 
 
 
STUDY PROTOCOL 
 
Principal Investigator Professor Waljit. S. Dhillo 
 
Title 
Head of Section, Endocrinology and Investigative Medicine 
Division of Diabetes, Endocrinology and Metabolism  
 
Institution 
Imperial College London 
 
Address: 
 
6th Floor Commonwealth Building 
Hammersmith Hospital 
150 Du Cane Road 
London 
W12 0NN 
 
Tel : 
+44 (0) 208 383 2820 
 
Fax : 
+44 (0) 208 383 8320 
 
Email : 
w.dhillo@imperial.ac.uk 
 
Protocol title 
 
Physiological study to determine the role of the melanocortin-
4 receptor in brain activity in women with hypoactive sexual 
desire disorder  
 
Main Sponsor 
Imperial College Healthcare NHS Trust 
Funder 
AMAG Pharmaceuticals Inc 
IRAS project ID 
262886 
Co-investigators 
Dr Tia Hunjan, Dr David Goldmeier, Dr Alexander Comninos, 
Dr Matt Wall, Dr Lisa Yang, Miss Lysia Demetriou, Dr 
Edouard Mills, Dr Layla Thurston.   
 
Statistician 
Mr Paul Bassett 
Version 
Date 
Reason for change  
Version 1.0 
12.04.2019 
Minor amendments 
Version 2.0 
24.04.2019 
Minor amendments 
Version 3.0 
11.06.2019 
Additional sections added 
Version 4.0 
31.07.2019 
Amendments following 
ethical review 
Version 5.0 
24.01.2020 
Minor amendments  

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
2 
Sponsor 
Imperial College Healthcare NHS Trust is the main research Sponsor for this study.  For 
further information regarding the sponsorship conditions, please contact the Head of 
Regulatory Compliance at: 
 
 
 
Joint Research Compliance Office 
Imperial College London and Imperial College Healthcare NHS Trust 
Room 215, Level 2, Medical School Building 
Norfolk Place 
London, W2 1PG 
Tel: 0207 594 9459/ 0207 594 1862 
http://www3.imperial.ac.uk/clinicalresearchgovernanceoffice  
 
 
Funder 
AMAG Pharmaceuticals Inc 
1100 Winter St, Waltham, 
MA 02451, USA 
 
This protocol describes the “Physiological study to determine the role of the melanocortin-4 
receptor in brain activity in women with hypoactive sexual desire disorder.  It provides 
information about procedures for entering participants.  Every care was taken in its drafting, 
but corrections or amendments may be necessary. These will be circulated to investigators in 
the study.  Problems relating to this study should be referred, in the first instance, to the 
Principal Investigator.  
 
This study will adhere to the principles outlined in the UK Policy Frame Work for Health and 
Social Care Research. It will be conducted in compliance with the protocol, the Data Protection 
Act and other regulatory requirements as appropriate.  
 
 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
3 
1. 
INTRODUCTION 
This study will be conducted according to International Council for Harmonisation Good 
Clinical Practice (GCP) guidelines, Declaration of Helskinki and local institutional research 
policies and procedures. 
1.1. 
Background 
1.1.1 
Hypoactive Sexual Desire Disorder 
Abnormalities of female sexual function are common. In the US, approximately 43% of adult 
women experience some form of sexual difficulty, with approximately 12% of these women 
reporting being distressed by their sexual dysfunction (Laumann 1999, Shifren 2008). Women 
may experience difficulties with sexual desire, arousal, or achieving orgasm, as well as 
dyspareunia (pain during intercourse). These disorders are commonly and broadly 
characterised as female sexual dysfunction (FSD). 
Abnormalities of female sexual desire or arousal, occurring as an acquired condition reflecting 
loss of prior function not associated with depression, relationship dysfunction, or other 
identifiable causes, and accompanied by distress, have been characterised as hypoactive sexual 
desire disorder (HSDD) or female sexual arousal disorder (FSAD), respectively. This 
classification is used in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, 
Text Revision (DSM IV TR) of the American Psychiatric Association (APA 2000). HSDD is 
the most common type of FSD. 
1.1.2 
Consequences of Hypoactive Sexual Desire Disorder 
HSDD can be devastating to premenopausal women and significantly impacts the quality of 
the relationships with their partners. HSDD is not only a women’s health concern, but also a 
couple’s problem. The loss of a fulfilling sex life causes women to suffer with stress, anxiety, 
sadness, and fears of abandonment, i.e., that their partners might become unfaithful or might 
want a divorce. Some feel angry, worthless, inadequate, like a “bad wife”, and experience a 
loss of self-esteem and self-confidence. Many women describe how losing physical closeness 
and intimacy causes loss of emotional closeness and distances partners from each other, 
causing tension and mistrust in the relationship. These themes are consistent with those 
expressed at public meetings (e.g. Voice of the patient 2014).   
1.1.3 
Treatment of Hypoactive Sexual Desire Disorder 
The female sexual response cycle is dependent on physiological, psychological, and social 
factors. Sexual therapy and education presently form the basis of treatment for HSDD and/or 
FSAD, with limited pharmacologic treatment options. While a few pharmacologic agents (e.g. 
testosterone and bupropion) have been or are being evaluated for the management of HSDD, 
there is only one approved treatment to date, Addyi® (flibanserin), but it is not licensed in the 
UK.  
Although transdermal testosterone (Intrinsa®) is able to restore testosterone levels to a normal 
range and improve sexual function in surgically postmenopausal women receiving estrogen 
replacement therapy, concerns around the safety associated with chronic use in this population 
prevented its approval (FDA Intrinsa Advisory Committee 2004; Spark 2005, Moynihan 2004). 
While flibanserin, a daily administered 5-HT agonist/5-HT2A antagonist, has been shown to 
improve the decreased desire and increased distress associated with HSDD, its use remains 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
4 
limited. This is due to a modest treatment effect, accompanied by a significant side effect 
profile including sedation, fatigue, and a dangerous interaction with alcohol, causing 
hypotension and syncope (Baid and Agarwal, 2018). As such, there remains significant 
limitations to the availability of safe and effective treatment options for women with HSDD.  
Therefore, studying the pathways involved provides a unique opportunity to address this unmet 
need with the ultimate aim of developing new therapies for women with HSDD. 
 
1.2. 
Melanocortin 4 receptor (MC4R) and sexual behaviour 
Previous work in animals suggests that MC4R stimulation may be involved in sexual behaviour 
and cause potential modulation of related brain pathways (Wilkberg et al., 2000, Pfaus et al., 
2004). However, the precise location of action remains unclear. Bremelanotide (BMT or PT-
141) is a synthetic cyclic heptapeptide and is a high-affinity ligand and agonist for melanocortin 
receptors (MCRs), particularly the type-4 receptor (MC4R) and so can be used to investigate 
this pathway further.  
 
1.3. 
Clinical Data with the MC4R agonist BMT 
BMT has been administered to approximately 3500 human subjects in 43 completed clinical 
studies using various formulations and modes of administration (intranasal [IN], intravenous 
[IV], or subcutaneous [SC]). During the development of BMT for the treatment of women with 
HSDD, more than 1500 subjects received at least 1 dose of SC BMT, 430 received IN BMT, 
and 10 received IV BMT. 
The dose range for SC that has been studied extends from 0.1 mg up to 10 mg, the maximum 
tolerated dose. A fixed dose of 1.75 mg SC was evaluated in premenopausal women with 
HSDD when administered once daily for up to 24 weeks in Phase 3 studies that also included 
an open-label extension (OLE) phase with up to 52 weeks of additional treatment.  
1.3.1 
Pharmacokinetics of BMT 
In two studies (PT-141-56 and PT-141-54), BMT absorption was rapid and complete after SC 
injection with the typical Tmax occurring at approximately 60 minutes in the plasma; the half-
life (t½) is approximately 2 to 3 hours. After an SC dose of 1.75 mg BMT, the typical maximum 
concentration (Cmax) in the plasma was 77.1 ng/mL. Human material studies showed that BMT 
had low binding to human plasma protein. The proposed biotransformation in humans is the 
breakdown of BMT into its constitutive amino acids through hydrolysis of the amide bonds. 
BMT and its breakdown products are predominantly renally cleared and excreted in the urine 
(64.8%); there is also some hepatic clearance but no BMT is detected in faeces.  
1.3.2 
Summary of the Efficacy of BMT in patients with HSDD 
Two identically-designed Phase 3, randomised, double-blind, placebo-controlled studies 
(BMT-301 and BMT-302 were conducted to evaluate the safety and efficacy of BMT 1.75 mg 
SC, self-administered on demand in approximately 1200 premenopausal women with HSDD 
(with or without decreased arousal). Bremelanotide 1.75 mg showed statistically significant 
and clinically meaningful treatment benefit compared with placebo on the co-primary 
endpoints of change from baseline in the Female Sexual Function Index (FSFI) Desire Domain 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
5 
and the Female Sexual Distress Scale – Desire/Arousal/Orgasm (FSDS-DAO) Question 13 
measure of distress associated with low sexual desire. The analysis of the co-primary endpoints 
in the pooled Phase 3 studies, which assessed the two key cardinal symptoms of HSDD (low 
sexual desire and related distress), demonstrated statistically significant increases in sexual 
desire from Baseline to End of Study (EOS) (p<0.0001) and reductions in related distress from 
low sexual desire from Baseline to EOS (p<0.0001) for BMT 1.75 mg compared to placebo. 
These effects were maintained in those who continued in the 52-week OLE phase of these 2 
studies.  
1.3.3 
Summary of Safety of BMT administration in humans 
Across the two Phase 3 studies (BMT 301 and BMT 302), nausea was the most common 
adverse event (AE); 16.2% of all BMT injections were associated with a nausea event. Most 
events (>95%) of nausea were mild to moderate in severity and most events resolved 
spontaneously without the need for concomitant treatment (87.3%).  
Less common treatment-emergent adverse events (TEAEs) associated with the use of BMT but 
reported in <2% of subjects and at an incidence greater than in the placebo group were restless 
leg syndrome, arthralgia, upper abdominal pain, and skin hyperpigmentation. Approximately 
20% of subjects discontinued long-term BMT due to an AE, the most common reasons being 
nausea (8.1%), headache (1.8%), vomiting (1.1%), and flushing (1.0%).  
Transient, mild increases in systolic blood pressure (BP) and diastolic BP were noted and 
peaked approximately 2 hours after BMT dosing, and were accompanied by similarly mild 
decreases in pulse rates, such that there were no increases in the overall heart rate (HR)-BP 
product. Effects disappeared within 4 hours of dosing. 
No clinically significant results were observed for clinical laboratory test results, 
electrocardiogram (ECG), heart rate, weight changes, depression or suicidal ideation, or 
changes in alcohol consumption.  
Overall, the totality of data supports the view that BMT is safe and generally well tolerated.  
1.4. 
Rationale for the current physiological study to determine the effects of MC4R 
activation (by BMT) on brain activity patterns in women with HSDD 
Two recent functional magnetic resonance imaging (fMRI) studies have examined the specific 
patterns of brain activation and sexual interest or response in women. Bianchi-Demicheli et al. 
conducted a study in 28 healthy, heterosexual, sexually active women, of which 13 had HSDD 
and 15 had no history of sexual dysfunction (NHSD), to compare the regional cerebral blood 
flow responses by fMRI between these 2 groups while they were looking at erotic vs. non-
erotic stimuli (Bianchi-Demicheli et al., 2011). The study demonstrated a differential 
recruitment of higher-order cognitive brain areas (inferior parietal lobule, inferior frontal 
gyrus) in subjects with HSDD compared with subjects with NHSD when viewing erotic 
stimuli, which was not seen for non-erotic stimuli. To investigate brain activation and sexual 
response, Arnow et al. conducted a study in 20 women with NHSD and 16 women with HSDD 
using an fMRI and potentiometer to permit continuous assessment of subjective arousal 
(Arnow et al., 2009). The authors concluded that exposure to erotic stimuli was associated with 
significant differences in both subjective arousal and brain activation in women with HSDD 
compared with women with NHSD across 3 time points. These findings support the use of 
fMRI as a tool to investigate brain activation and sexual function in women with HSDD. 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
6 
The primary purpose of this study is to examine brain activation patterns (by fMRI) during 
visual erotic stimuli in premenopausal women with HSDD in response to MC4R activation (by 
BMT). Data gathered from this study will help us understand which areas of the brain BMT 
activates to mediates its effects and therefore better understand the physiological roles of the 
MC4 receptor. 
 
Primary hypothesis: MC4R activation causes differential brain activity patterns compared to 
placebo in response to visual erotic stimuli. 
 
1.4.1 
Study Population Rationale 
The population for this study is consistent with the premenopausal population of women with 
HSDD studied in the existing literature and in the BMT Phase 3 clinical trials. In this study, 
subjects who are right-hand dominant will be recruited since subjects will be required to 
operate a response box with their right hand while in the scanner, and also because handedness 
has established implications for the organisation of functional regions in the brain (e.g. 
Cuzzocreo et al., 2009), which can be a potential confounding factor.  
 
Dose Justification for the MC4R agonist BMT 
Based on clinical studies, the 1.75 mg SC dose of BMT was shown to be safe and effective in 
premenopausal women with HSDD.  
 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
7 
2. 
STUDY OBJECTIVES 
2.1. 
Primary Objective 
The primary objective of the study is to evaluate the effect of MC4R activation on brain activity 
patterns using functional neuroimaging (fMRI) during visual erotic stimuli in premenopausal 
women with HSDD. 
2.2. 
Secondary Objectives 
Secondary objectives of the study include the following: 
• To evaluate the effect of MC4R activation on behavioral psychometric measures 
relating to sexual arousal during visual erotic stimuli in premenopausal women with 
HSDD 
• To evaluate hormonal profiles following MC4R activation in premenopausal women 
with HSDD  
 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
8 
3. 
STUDY DESIGN 
3.1. 
General Design 
This is a randomised, double-blind, placebo-controlled, two-way crossover physiological 
study. It is designed to evaluate the effects of MC4R activation on brain activity patterns and 
behavioral psychometric measures of sexual arousal during visual erotic stimuli in 
approximately 40 right-handed, heterosexual, premenopausal women ≥18 years of age with 
HSDD (≥6-month duration) (see power calculation for determination of sample size).  
The study will consist of two Phases: Screening & Intervention (MC4R agonist (BMT) or 
placebo). (Figure 1).   
• Screening Phase (Visit 0).   
• During the Intervention Phase, eligible subjects will be randomised (1:1) to one of 
two intervention sequences (AB or BA). Subjects will receive a single dose of BMT 
or matching placebo, administered SC, during each of the two Intervention Phases 
(Visit 1 and Visit 2) based on the randomisation intervention sequence they are 
assigned. The crossover design, which allows subjects to serve as their own control, 
will minimise inter-participant variability. Participants will return for Visit 2 in the 
same phase of the menstrual cycle of a subsequent month. 
• Subjects who are randomised to intervention sequence AB will receive BMT 1.75 
mg SC (Intervention A) during Intervention Phase 1 (Visit 1) and will receive 
placebo (Intervention B) during Intervention Phase 2 (Visit 2). Subjects who are 
randomised to intervention sequence BA will receive placebo (Intervention B) 
during Intervention Phase 1 (Visit 1) and will receive BMT 1.75 mg SC 
(Intervention A) during Intervention Phase 2 (Visit 2). Subjects will remain at the 
study centre for approximately seven hours during each of the Intervention Phases. 
Subjects may be required to remain at the study centre longer at the discretion of 
the Investigator. 
 
Figure 1: 
Study Schematic  
 
 
Visit 0 
Visit 2
Vi it 0
Visit 1 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
9 
4. 
SUBJECT SELECTION 
 
We will recruit approximately 40 women to allow for subject and technical drop-out (e.g. head 
movement during fMRI), aiming for a minimum of 30 women in the final study who complete 
the full protocol successfully.  
We will collaborate with the Sexual Medicine clinic to identify potential participants, as well 
as advertise via print (including local and regional newspapers, transport network), radio and 
online advertisements. Additionally, we will liaise with the North West London Clinical 
Research Network (CRN) to contact potentially eligible patients via their GP practice (via letter 
or SMS). We will also inform GP’s regarding the study who can opportunistically provide 
contact details to patients they see in their practice who may be eligible and display posters in 
GP practices. Potential participants who contact us via advertisements will initially be 
electronically sent a participant information sheet and self-report questionnaire, to be returned 
via email. If, following this, they are keen to take part and no obvious exclusion criteria are 
detected, they will be screened via telephone by a sexual health nurse using a questionnaire. If 
they appear eligible and are keen to participate, they will then be invited to attend a screening 
interview, where further questions regarding the study will be answered. 
4.1. 
Inclusion Criteria 
A subject will be eligible for enrollment in the study if all the following criteria apply: 
1. Heterosexual premenopausal females ≥ 18 years of age with normal menstrual cycles 
≤ 35 days. 
2. Right hand dominant. 
3. Body mass index (BMI) 18-35kg/m2.  
4. Currently in a relationship with a male partner and the relationship has been stable for 
at least 6 months before screening. 
5. Male sexual partner classified as “not impotent” on the Massachusetts Male Aging 
Study (MMAS) (O’Donnell et al., 2004) single-question assessment of erectile 
dysfunction.  
6. In the subject’s opinion, previously experienced “normal sexual function,” defined as a 
normal level of desire at some point in the past, for a period of at least 2 years. 
7. For all subjects of childbearing potential who are sexually active, agree to routinely use 
adequate non-hormonal contraception from randomisation throughout the duration of 
the study and for 30 days after.  
8. For at least 6 months before Screening, met the diagnostic criteria for HSDD according 
to the Diagnostic Screening Guide for HSDD (Appendix B), including categorisation 
of the sexual dysfunction as both acquired (versus lifelong) and generalised (versus 
situational). 
9. All of the following at Screening: 
a. Patient Health Questionnaire (PHQ-9) (Kroenke et al., 2001) total score is <10. 
b. PHQ-9 score for Question 9 is 0. 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
10
a. Either Female Sexual Function Index (FSFI) (Appendix C) total score ≤26 if 
diagnosed with HSDD (with or without symptoms of decreased arousal) or 
subjects diagnosed with HSDD only (without symptoms of decreased arousal), 
FSFI desire domain score of ≤5 (regardless of total FSFI score). 
b. Female Sexual Distress Scale - Desire/Arousal/Orgasm (FSDS-DAO) (Appendix 
D) total score is >18. 
10. Capable of understanding and complying with the protocol requirements and available 
for the duration of the study. 
11. Subjects must have prior experience in viewing sexually explicit material.  
4.2. 
Exclusion Criteria 
A subject will not be eligible for enrollment in the study if any of the following criteria apply: 
1. Cardiovascular disease  
2. Current diagnosis of uncontrolled hypertension defined as: 
a. Two sequential assessments (seated, approximately 4 minutes apart and no more 
than 15 minutes apart) with readings above 140 mmHg systolic BP or 90 mmHg 
diastolic BP, and upon repeat at least 24 hours later. 
b. Treatment for hypertension that has been changed at least once in the 4 weeks 
prior to Screening. 
3. Any other medical condition that is unstable or uncontrolled despite current therapy. 
4. Previously received BMT. 
5. A history of unresolved sexual trauma or abuse. 
6. Female subjects who are pregnant, intend to become pregnant, are breastfeeding, have 
a positive serum/urine pregnancy test, or are not willing to use effective contraceptive 
precautions during the study. 
7. Participated in any research study within the preceding 30 days of screening.  
8. Any FSD other than acquired HSDD with or without decreased arousal (e.g. lifelong 
anorgasmia, sexual pain disorder, sexual aversion disorder, primary female sexual 
arousal disorder). 
9. FSD caused by untreated endocrine disease (e.g. hypopituitarism, hypothyroidism, 
diabetes mellitus). 
10. Acute or chronic hepatitis. 
11. In the Investigator’s opinion, any urologic or gynecologic condition, such as 
condyloma, uterine fibroids, vulvar or vaginal lesions, vulvodynia, vaginismus, or 
pelvic pain that may contribute to impaired sexual activity and function or be a cause 
of the FSD or that may interfere with the subject’s ability to comply with study 
procedures. 
12. Receiving any treatment for HSDD (e.g. psychotherapy, physical therapy) at the time 
of Screening. 
13. Has used any of the following types of medications, which are prohibited during the 
study: 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
11
a. Implanted or injected testosterone product within 6 months of Screening. 
b. Within 3 months of Screening: 
− Neuroleptics (e.g. risperidone) 
− Lithium (e.g. lithium carbonate) 
− Antidepressants (e.g. amitriptyline, fluoxetine, bupropion) 
− Mood stabilisers (e.g. valproate) 
− Benzodiazepines (e.g. lorazepam, diazepam) 
− Cognitive enhancers or stimulants (e.g. donepezil or Adderall®) 
− Centrally-acting antihypertensives (e.g. clonidine) 
− Any other prescription, non-prescription, hormonal, herbal, or nutritional 
medication or supplement that the investigators believe would confound the 
results of the study (e.g. St. John’s wort, black cohosh, dehydroepiandrosterone, 
dehydroepiandrosterone sulfate) 
− γ-Aminobutyric 
acid 
agonists 
(e.g. 
Ambien® 
[zolpidem], 
Lunesta® 
[eszopiclone]) 
c. Topical or systemic androgen therapy within 30 days of Screening. 
d. Subject is unwilling or unable to refrain from using the aforementioned products 
for the duration of the study. 
14. Mental health history that includes any of the following: 
a. Psychosis, bipolar disorder, depression, and/or alcohol/substance abuse; depression 
or alcohol/substance abuse that resolved >1 year prior to Screening/Visit 0 will not 
be exclusionary. 
b. Prior suicide attempt or increased suicidality as indicated by a score greater than 
zero on Questions 1-5 inclusive (interpreted increased risk) and/or Question 20 
(interpreted history of suicide) of the Beck Scale for Suicidal Ideation (BSS) (Kleim 
et al., 2017). 
15. Any abnormality in vision that would impair viewing images. 
16. Any contraindication to MRI or otherwise unable to undergo an MRI (e.g. pacemaker, 
recent wound clips, severe claustrophobia, unable to lay flat). 
17. Any other condition or subject responsibility that in the Investigator’s opinion may 
interfere with a subject’s ability to give informed consent or adhere to the protocol or 
has the potential to interfere with the studied endpoints or serves as a contraindication 
to the subject’s participation in the study. 
4.3. 
Criteria for Randomisation  
Subjects who sign consent and meet eligibility criteria may be randomised to the study by an 
independent investigator. All subjects will be randomised in a 1:1 ratio in a two-way crossover 
design to one of two intervention sequences: AB or BA, where BMT is Intervention A, and 
placebo is Intervention B. Blinding will be performed by a member of the research team not 
directly involved in running the study, following the dispensing of the medication from 
pharmacy.  

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
12
5. 
STUDY OUTCOMES 
 
5.1. 
Primary Endpoint  
The primary endpoint is change in brain activity patterns with MC4R activation compared to 
placebo in scanning session 1 (SS1) as measured by fMRI during visual erotic stimuli. 
5.2. 
Secondary Endpoints  
• Change in brain activity patterns with MC4R activation compared to placebo in 
scanning session 2 (SS2) as measured by fMRI during visual erotic stimuli. 
• Change in psychometric measures related to sexual arousal with MC4R activation 
compared to placebo in SS1 as measured with a behavioral potentiometer during 
visual erotic stimuli. 
• Change in psychometric measures related to sexual arousal with MC4R activation 
compared to placebo in SS2 as measured with a behavioral potentiometer during 
visual erotic stimuli. 
5.3. 
Exploratory Endpoints 
 
Exploratory endpoints include the following: 
• Changes in blood and hormonal parameters including follicle stimulating hormone 
(SH), luteinizing hormone (LH), kisspeptin, oestradiol, progesterone, sex-hormone 
binding globulin (SHBG) and testosterone levels. 
 
5.4. 
Safety Assessment 
 
Safety will be assessed based on: 
• incidence of adverse events (AE’s), clinical laboratory assessments (haematology, 
chemistry, and urinalysis), vital signs (systolic and diastolic BP, pulse rate, and oral 
temperature), 12-lead ECG, and physical examination findings. 
 
 
 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
13
6. 
STUDY INTERVENTION 
6.1. 
Description of Study Intervention 
The two study interventions are: 
• MC4R agonist (BMT 1.75 mg SC - prefilled autoinjector containing 1.75 mg BMT 
in a 0.3 mL solution volume) 
• Placebo (1.75 mg equivalent SC - prefilled autoinjector containing BMT 
formulation without the active ingredient in a 0.3 mL solution volume) 
 
6.2  
     Supply 
• BMT autoinjectors will be shipped in a validated shipping container with cold 
packs.  
• The study intervention will be supplied from AMAG’s packager in the United 
Kingdom.  
 
6.3  
      Storage 
• All study interventions will be stored in a secure, limited access area (Imperial 
College Healthcare Trust Pharmacy) and refrigerated at 2ºC to 8ºC. It should be 
removed from the refrigerator approximately 45 minutes prior to dosing to allow 
the intervention to reach room temperature (20°C to 25°C ) prior to dosing,  
 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
14
7. 
STUDY PROCEDURES 
7.1. 
Subject Informed Consent, Screening, and Randomisation  
7.1.1 
Subject Informed Consent 
Study personnel will adhere to GCP guidelines when obtaining consent from any potential 
study candidate, including explaining the rationale for and the details of the study, the risks of 
study intervention, and the extent of involvement. An information leaflet will be provided, with 
at least 24 hours for consideration of participation. Once the essential information has been 
provided to the subject and fully explained by the Investigator (or a qualified designee), and it 
is felt that the subject understands the implications and risks of participating in the study, the 
approved informed consent form (ICF) will be signed and dated. The right of the participant to 
refuse to participate without giving reasons will be respected. 
The subject will be given a copy of the ICF, and the original will be maintained with the 
subject’s record. A note summarising the consent process will also be included in the subject’s 
record. 
7.1.2 
Procedures for Assigning Subjects to Intervention Groups  
Eligible subjects who meet all inclusion criteria and do not meet any exclusion criteria will be 
randomised. Randomisation will be carried out using standard procedures. Randomisation 
numbers will not be reused for any reason.  
7.2. 
Procedures by Study Phase  
The assessments and procedures to be completed during each of the study phases are described 
in the sections that follow and in the Schedule of Events and Procedures provided in Appendix 
A. Detailed descriptions of the study assessments and measurements are provided in 8. 
Screening Phase (Visit 0) 
The following will be performed during the Screening Visit including: 
• review inclusion/exclusion criteria for eligibility 
• collect demographics 
• collect medical, social, sexual, and medication history 
• perform diagnostic screening for HSDD  
• perform vital signs assessment (systolic and diastolic BP, heart rate, temperature) 
• perform comprehensive physical examination 
• perform 12-lead ECG 
• collect blood and urine for clinical laboratory tests including: 
− hematology 
− serum chemistry 
− urinalysis 
− FSH, LH, oestradiol, progesterone, prolactin, dehydroepiandrosterone sulphate 
(DHEAS), androstenedione & testosterone 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
15
− urine pregnancy test 
− DNA analysis (if patient consents) to assess for novel genes implicated in the 
aetiology of HSDD 
• have subject complete questionnaires/assessments such as: 
− PHQ-9 
− BSS  
− Decreased Sexual Desire Screener (DSDS) (Clayton et al., 2009) 
− FSFI 
− FSDS-DAO 
− MMAS 
• schedule study visits for participants who are eligible and available for the duration 
of the study 
• advise participants to consume a normal breakfast on day of study and abstain from 
sexual activity, alcohol, caffeine and tobacco from midnight before their study visits 
• MRI safety questionnaire 
7.2.1 
Intervention Phase (Visits 1 and 2) 
Visit 1 
Visit 1 will occur after Screening (Visit 0), on day 1-7 of the menstrual cycle. Subjects will be 
randomised and the following procedures will be performed: 
 
• On arrival 
− review and confirm study eligibility 
− perform vital signs assessment (systolic and diastolic BP, heart rate, 
temperature) 
− perform symptom-driven physical examination 
− collect blood and urine for clinical laboratory tests (haematology, serum 
chemistry, urinalysis) 
− perform urine pregnancy test 
− review concomitant medications 
− MRI safety questionnaire 
• Prior to intervention 
− remove intervention autoinjector from assigned study kit; warm to room 
temperature 
− collect arousal/psychometric data using behavioral potentiometer (including the 
Visual Analogue Scale (VAS), the State-Trait Anxiety Inventory (STAI Y1 and 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
16
Y2), the Sexual Arousal and Desire Inventory (SADI) and the Positive and 
Negative Affect Schedule (PANAS) at the end of scanning component of 
session (see Appendices E to I). 
• Post-intervention assessments: 
− administer intervention based on randomisation assignment 
− collect blood at time-points: -15, 0 (SC injection), 15, 45, 60, 75, 90, 120, 150, 
180, 210, 240, 270, 300 (14 timepoints total). A maximum of 12ml will be taken 
at each time-point. The total volume of blood collected over both study visits 
will not exceed 340ml.  
− During SS1: 
o perform fMRI in accordance with Imaging Manual instructions (including 
functional MRI scan (commencing t=45mins) and anatomical MRI scan) 
o Exposure to visual erotic stimuli as well as other tasks designed to elicit 
brain responses related to emotional, sensory, or cognitive functions. 
o collect psychometric data using behavioral potentiometer alongside session 
(arousal handheld device in scanner and psychometric/behavioral 
potentiometer questionnaires including the Visual Analogue Scale (VAS), 
the State-Trait Anxiety Inventory (STAI Y2), the Sexual Arousal and Desire 
Inventory (SADI) and the Positive and Negative Affect Schedule (PANAS) 
at the end of scanning component of session (see Appendices E to I).  
− During SS2: 
o perform fMRI (and anatomical scan) in accordance with Imaging Manual 
instructions (commencing t=240mins) 
o Exposure to stimuli as per SS1.  
o collect psychometric data using behavioral potentiometer alongside session 
(arousal handheld device in scanner and psychometric/behavioral 
potentiometer questionnaires including the Visual Analogue Scale (VAS), 
the State-Trait Anxiety Inventory (STAI Y2), the Sexual Arousal and Desire 
Inventory (SADI), the Positive and Negative Affect Schedule (PANAS) and 
the D2 Test of Attention at the end of scanning component of session (see 
Appendices E to I).  
 
Visit 2 
This will occur on day 1-7 of a subsequent menstrual cycle, to allow for the study to be carried 
out in the same part of the menstrual cycle on each visit.  
The following procedures will be performed: 
• On arrival 
- 
As described for Visit 1 
• Prior to intervention  
- 
As described for Visit 1 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
17
• Post-intervention assessments 
- 
As described for Visit 1 
 
Follow-up 
Participants will be sent a short questionnaire 24 hours after the study to assess the perceived 
duration of effect of BMT (see Appendix J). 
7.3. 
Subject Discontinuation and Criteria for Withdrawal  
7.3.1 
Subject Withdrawal 
All participants are free to withdraw at any time without giving reasons and without prejudicing 
future treatment.  

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
18
8. 
STUDY ASSESSMENTS AND MEASUREMENTS 
8.1. 
Vital Signs 
Systolic and diastolic BP, heart rate, and temperature will be performed at Screening and at 
Visits 1 and 2 before administration of the intervention and before/after each SS.   
8.2. 
Physical Examination 
A comprehensive physical examination including height, weight, BMI, and assessment of all 
body systems will be performed at Screening. Subsequent physical examinations at Visits 1 
and 2 will be symptom-driven based on any AEs, subject complaints about physical state, or 
subject reported changes in physical state. 
8.3. 
12-Lead Electrocardiogram 
A 12-lead ECG will be performed at Screening and reviewed by a qualified clinician designated 
by the Principal Investigator to read and interpret the results. Any anomalies will be managed 
as clinically appropriate and the GP of the patient informed. 
8.4. 
Clinical Laboratory Tests and Visit Assessments 
Urine pregnancy tests will be conducted at Screening and at the start of each study visit. 
Clinical laboratory tests will be performed by a clinical laboratory.  
Subjects will be fully informed that the study is evaluating sexual desire brain activity patterns. 
In conjunction with each fMRI scan, subjective desire will be measured with a behavioral 
potentiometer.  
8.4.1 
Safety Assessments 
Safety will be monitored with the following assessments: incidence of AEs, vital signs, clinical 
laboratory tests, and physical examination. 
 
8.5  
     MRI scans 
Prior to the first functional MRI scan, an anatomical MRI scan will be performed. These 
anatomical scans will be reviewed by a qualified neuroradiologist and if any abnormalities are 
detected, the patient’s GP will be informed, with their consent. They will be withdrawn from 
the study, in the case of abnormalities that would affect the study.   
 
 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
19
9. 
SAFETY MONITORING AND RISK MANAGEMENT 
9.1. 
Safety Events and Reporting 
During the study: 
Any potential adverse events of the study will be reviewed regularly by the Chief Investigator, 
Professor Dhillo, and the other investigators. The safety of the subjects is of the highest 
importance throughout the study. An internal audit will be completed at the end of the study. 
Study progress and safety will be regularly reviewed in fortnightly meetings. A formal 
monitoring committee is not deemed necessary as the MC4R agonist (BMT) has been 
administered safely previously. If any subjects come to harm as a result of taking part in this 
research study the study will be terminated.  
Adverse Events:  
Adverse Event (AE): any untoward medical occurrence in a patient or clinical study subject.  
Serious Adverse Event (SAE): any untoward and unexpected medical occurrence or effect that:  
· 
Results in death   
· 
Is life-threatening – refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event which hypothetically might have caused 
death if it were more severe  
· 
Requires hospitalisation, or prolongation of existing inpatients’ hospitalisation  
· 
Results in persistent or significant disability or incapacity 
· 
Is a congenital anomaly or birth defect 
Medical judgement will be exercised in deciding whether an AE is serious in other situations. 
Important AEs that are not immediately life-threatening or do not result in death or 
hospitalisation but may jeopardise the subject or may require intervention to prevent one of the 
other outcomes listed in the definition above, will also be considered serious.  
Reporting Procedures:  
All adverse events will be reported. Depending on the nature of the event the reporting 
procedures below will be followed. Any questions concerning adverse event reporting will be 
directed to Professor Waljit Dhillo in the first instance.  
Non serious AE’s  
All such events, whether expected or not, will be recorded.  
Serious AE’s  
An SAE form will be completed and faxed to Professor Waljit Dhillo within 24 hours. 
However, relapse and death due to unrelated pre-existing conditions, and hospitalisations for 
elective treatment of a pre-existing condition do not need reporting as SAEs.  
All SAEs should be reported to the local REC committee where in the opinion of the Chief 
Investigator, Professor Waljit Dhillo, the event was: 
· 
‘related’, i.e. resulted from the administration of any of the research procedures; and 
· 
‘unexpected’, i.e. an event that is not listed in the protocol as an expected occurrence  

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
20
Reports of related and unexpected SAEs will be submitted within 15 days of the Chief 
Investigator, Professor Waljit Dhillo, becoming aware of the event, using the National 
Research Ethics Service (NRES) SAE form for non-IMP studies. 
Local investigators will report any SAEs as required by their Local Research Ethics 
Committee, Sponsor and/or Research & Development Office. 
All AE’s/SAE’s must be reported during the study, regardless of relationship to study 
intervention or clinical significance. 
9.1.1 
Pregnancy 
In the unlikely event that a female subject becomes pregnant at any time during the study, the 
Investigator must notify the Sponsor (Imperial College Healthcare NHS Trust) immediately 
(within 24 hours) so as to facilitate discussion and implementation of necessary follow-up 
measures and to enable the Sponsor to submit necessary reports to the ethics committee. The 
Investigator will be required to follow the subject and pregnancy through delivery (or earlier 
loss/termination) and report any congenital anomalies or birth defects. Additional information 
may be requested to meet regulatory reporting requirements. 
9.2. 
Unblinding Procedures 
Only in the case of an emergency, when the identity of the study intervention is essential for 
the clinical management or welfare of the subject, can an Investigator request unblinding of a 
subject’s intervention assignment.  

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
21
10. 
STATISTICAL PLAN 
10.1. 
Analysis Populations 
This study will include the following analysis populations: 
• Randomised Population: all subjects who are assigned an intervention sequence via 
randomisation in the Intervention Phase 
• Intent-to-Treat (ITT) Population: all randomised subjects who receive any study 
intervention in the Intervention Phase 
• Completer Population: all randomised subjects who complete both Visit 1 and 2 in 
the Intervention Phase 
• Per-Protocol Population: all randomised subjects who complete both Visit 1 and 2 
in the Intervention Phase and have no major protocol deviations that would 
confound results 
• Safety Population: all subjects who receive any study intervention in the 
Intervention Phase 
Subject allocation to analysis populations, including the review of major protocol deviations 
and assignment to the Per-Protocol Population, will be based on a blinded review prior to 
database lock. 
10.2. 
Statistical Methods 
10.2.1 
General Considerations 
All individual subject data for all individual subjects randomised to an intervention sequence 
will be presented in data listings. 
Data collected in this study will be presented using summary tables and data listings. 
Continuous variables will be summarised using descriptive statistics, such as the number of 
subjects (n), mean, median, standard deviation (SD), standard error (SE), minimum, and 
maximum. Categorical variables will be summarised by frequencies and percentages when 
appropriate. All statistical tests will be two-sided at the 5% significance level, unless otherwise 
noted.  
10.2.2 
Demographics and Baseline Characteristics 
Subject disposition, demographic and baseline characteristics, prior and concomitant 
medications, and other background characteristics will be summarised.  

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
22
10.2.3 
Endpoint Analyses 
Endpoint analyses (see section 5 for endpoints) will be performed on populations as above. 
Analyses will be performed based on randomised intervention (Completer and Per-Protocol 
Populations as appropriate).  
The MRI data will be processed and analysed using current best practice methods, which will 
include (but may not be limited to)  application of the General Linear Model (GLM) for 
neuroimaging data. Robust methods of correcting for multiple comparisons (e.g. permutation 
testing) will be used for statistical analysis and thresholding of the statistical brain images.  
Brain activation patterns will be presented by intervention and analysed by whole-brain and 
region of interest (including amygdala, thalamus, posterior cingulate cortex and entorhinal 
region.  
Correlations will be explored between brain activation and behavioral data, corrected for visit 
order as appropriate (including Pearson and Partial Correlation testing).  
10.2.4 
Safety Analyses 
Safety analyses will be performed on the Safety Population; all analyses will be performed 
based on intervention received. Clinical laboratory results, vital signs, and 12-lead ECG results 
will be summarised using descriptive statistics (n, mean, SD, SE, median, minimum, and 
maximum values, as appropriate) by intervention and time point, and all data will be listed.  
10.3. 
Sample Size Justification 
The final projected sample size (approximately 30) has been determined by appropriate power 
calculation and is in line with the recommended n number required for neuroimaging clinical 
studies to be powered appropriately to be able to observe significant changes in fMRI brain 
activation patterns (Murphy and Garavan, 2004).  
10.3.1   Power calculation  
There are no previous functional magnetic resonance imaging (fMRI) studies examining the 
role of the melanocortin-4 receptor (MC4R) in hypoactive sexual desire disorder (HSDD). 
However, data from a previous fMRI study (Comninos et al., 2017) examining a similar 
scenario (kisspeptin hormonal administration effects on fMRI sexual brain activity) can be used 
to estimate requirements for the current study. The amygdala is an important structure involved 
in the processing of sexual stimuli in healthy participants as well as patients with HSDD and 
so is an appropriate reference point. (Woodward et al., 2013). This study shows that kisspeptin 
enhances blood oxygen level dependent (BOLD) signal change in the amygdala by mean 
0.74% and standard deviation 0.38% compared to vehicle (mean 0.48%, standard deviation 
0.51%).  
We are anticipating a similar response in this study and have performed sample size 
calculations for the study using these data. With a 5% significance level, and 80% power, and 
assuming a correlation between Bremelanotide (an MC4R agonist) and vehicle means of 0.4, 
a sample size of 31 patients is calculated. To allow for natural variation in responses, drop-out 
and exclusion rate (e.g. a priori head movement > 2mm) of 20%, it is planned to recruit a total 
of approximately 40 patients to the study. 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
23
11.  
REGULATORY ISSUES  
11.1 Ethical Approval 
The Principal Investigator will obtain approval from the … Research Ethics Committee (REC) 
and Health Research Authority (HRA). The study must also receive confirmation of capacity 
and capability from each participating NHS Trust before accepting participants into the study 
or any research activity is carried out. The study will be conducted in accordance with the 
recommendations for physicians involved in research on human subjects adopted by the 18th 
World Medical Assembly, Helsinki 1964 and later revisions. 
11.2 Confidentiality  
The Chief Investigator, Professor Waljit Dhillo is the data custodian. He will preserve the 
confidentiality of participants taking part in the study under the Data Protection Act 2018. Their 
data will only be accessed by members of the research team. All samples will be coded by the 
research team, and these codes will only be accessible to researchers directly involved with the 
study. Details stored on Imperial College London computers will be password-encrypted and 
will only be accessed by the researchers involved in the study. Written confidential patient 
notes will also be kept at Imperial College London, which will contain personal information 
and medical history of participants. All records will be stored in secure containment for 5 years 
after the study on the Hammersmith Hospital campus, Imperial College London, under the 
authority of Professor Dhillo 
If participants are to be enrolled in the study, we will ask their consent to view their medical 
records. If they are not registered with Imperial College Healthcare NHS Trust (ICHT), a set 
of ICHT notes will be created. Personal addresses and contact details are required for 
communication with the participants during the study. This information is held solely for 
communication between the researchers and participants. 
Information held on NHS computers is solely for the purpose of hospital booking, routine 
sample collection and analysis (e.g. for the screening visit). This information is 
password−encrypted, in a similar manner to that of other hospital patients. Written confidential 
patient notes will also be kept, which will contain personal information and medical history of 
participants. 
Personally Identifiable Information (PII) will be entered into Invicro's Patient Information 
Management System which assigns them a unique six-digit ID. This six-digit ID is used within 
the Radiology Information System (RIS) for the purposes of verifying the identity of 
participants immediately prior to the scans. The six-digit participant identification code is the 
only identifier subsequently used when acquiring the imaging data. The imaging data (and any 
ancillary data generated) is therefore pseudo-anonymised (code is kept in case of need to un-
break blinding). Invicro operates under a highly-secure and enterprise-class computing 
environment, and fully complies with Good Clinical Practice (GCP) guidelines and Data 
Protection Act (2018) directives with regard to participant PII. Invicro pseudo-anonymised data 
will be stored indefinitely.  Invicro also holds the study file and consent forms, which are 
archived indefinitely in a secure off-site document storage facility. 
AMAG Pharmaceuticals, Inc. will receive anonymised data relating to this study. 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
24
11.3 Indemnity 
Imperial College Healthcare NHS Trust holds standard NHS Hospital Indemnity and Insurance 
cover with NHS resolution for NHS Trusts in England, which apply to this study.  
Separate insurance is held by Invicro for the conduct at their site. 
11.4 Funding 
AMAG Pharmaceuticals Inc are funding this study. Participants will receive £150 per 
completed study visit to cover expenses including travel costs, time off work and lost earnings, 
in keeping with NIHR guidelines.  
11.5 Audits  
The study may be subject to inspection and audit by Imperial College Healthcare NHS Trust 
under their remit as Sponsor, the Study Coordination Centre and other regulatory bodies to 
ensure adherence to GCP.  
11.6 Sample storage 
At the end of the study, the data will be kept in locked storage in the Department of 
Investigative Medicine on the Hammersmith Hospital campus, Imperial College London, under 
the authority of Professor Dhillo. On a day−to−day basis, data will be managed by the 
department's senior administrative manager. Only the researchers will have access to the data. 
Samples will be stored for 5 years. 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
25
12. REFERENCES 
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, IV 
TR Edition. Arlington, VA: American Psychiatric Association; 2000. 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition. Arlington, VA: American Psychiatric Association; 2013. 
Arnow BA, et al. Women with hypoactive sexual desire disorder compared to normal females: 
a functional magnetic resonance imaging study. Neuroscience 2009;158:484-502. 
Baid R & Agarwal R. Flibanserin: A controversial drug for female hypoactive sexual desire 
disorder. Ind Psychiatry J. 27(1): 154-157. 
Bianchi-Demicheli F, et al. Neural bases of hypoactive sexual desire disorder in women: an 
event-related fMRI study. J Sex Med 2011;8:2546-59. 
Clayton A et al. Validity of the decreased sexual desire screener for diagnosing hypoactive 
sexual desire disorder. J Sex & Marital Ther. 2009;39:132-143. 
Cuzzocreo, J. L et al. Effect of handedness on fMRI activation in the medial temporal lobe 
during an auditory verbal memory task. Human brain mapping. 2009. 30(4), 1271-1278. 
FDA Voice of the Patient: Female Sexual Dysfunction. Public Meeting: October 27, 2014. 
Kliem S et al. German Beck Scale for Suicide Ideation (BSS): psychometric properties from a 
representative population survey. BMC Psychiatry. 2017. 4; 17(1): 389.  
Kroenke et al. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 
2001. 16(9): 606-13.  
Laumann EO, Paik A, and Rosen RC. Sexual dysfunction in the United States: prevalence and 
predictors. JAMA 1999;281:537-44. 
Moynihan R. FDA panel rejects testosterone patch for women on safety grounds. BMJ. 
2004;329(7479):1363. 
O’Donnell AB et al., The Validity of a Single-question Self-report of Erectile Dysfunction. J 
Gen Intern Med. 2005. 20 (6): 515-9. 
Pfaus JG et al., Selective facilitation of sexual solicitation in the female rat by a melanocortin 
receptor agonist. Proc. Natl Acad. Sci. USA. 2004. 101(27), 10201–10204.  
Procter & Gamble Pharmaceuticals I. Advisory Committee Briefing Document: Intrinsa 
(testosterone 
transdermal 
system). 
2004. 
http://www.fda.gov/ohms/dockets/ac/04/briefing/2004-4082b1.htm. 
Shifren JL, et al. Sexual problems and distress in United States women: prevalence and 
correlates. Obstet Gynecol 2008;112:970-978. 
Spark RF. Intrinsa fails to impress FDA advisory panel. Int J Impot Res 2005;17(3):283-4.  
Soules et al. Executive Summary: Stages of Reproductive Aging Workshop (STRAW) Park 
City, Utah, July, 2001. Menopause. 2001:8(6):402-7. 
Murphy K, Garavan H. An empirical investigation into the number of subjects required for an 
event-related fMRI study. Neuroimage. 2004;22(2):8 79–885. 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
26
 
Wilkberg JE et al. New aspects of the melanocortins and their receptors. Pharmacol. Res. 2000. 
42(5): 393-420. 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
27
Appendix A: 
STUDY FLOWCHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables  
Screening 
(Visit 0) 
Intervention 
phase  
(Visit 1) 
Intervention 
Phase  
(Visit 2) 
Informed Consent Form (ICF) 
X 
  
  
Review inclusion/exclusion criteria 
X 
X 
X 
Demographics 
X 
 
 
Medical, social and sexual history 
X 
  
  
Review medications 
X 
X 
X 
Perform diagnostic screening for 
HSDD  
X 
 
 
Perform baseline screening 
questionnaires: PHQ-9, BSS, FSFI, 
FSDS-DAO, MMAS 
X 
 
 
Vital signs  
X 
X 
X 
12-lead ECG  
X 
  
  
Urine pregnancy test 
X 
X 
X 
Physical exam 
X 
X 
X 
Clinical laboratory tests 
X 
X 
X 
Randomisation 
  
X 
Continued eligibility assessment 
 
X 
X 
Administer intervention BMT/placebo 
  
X 
X 
fMRI & behavioral potentiometer 
(including handheld device and 
questionnaires such as VAS, STAI Y1 
and Y2, SADI, PANAS, D2 Test of 
Attention)  
  
X 
X 
Review adverse events 
  
X 
X 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
28
APPENDIX B: Diagnostic Screening Guide For HSDD 
 
Introduction: Ask various questions to make the subject feel comfortable and also to gain some insight 
into the subject’s life, such as: 
• 
Tell me a little about yourself please. Then, if the conversation falters a bit, provide her with 
some leading questions, such as: 
- 
Do you work? What job do you have? What is your typical day like? 
- 
Do you have children? If yes, what are their ages? How are they doing? 
• 
Why are you participating in this study? 
- 
Does your partner know you are participating in a study? 
- 
Is the partner supportive of your being here? 
1) Please briefly describe your current relationship. 
a) How long have you been together? How long have you been sexually intimate? 
b) Do you feel positively about your relationship with your partner? 
c) Do you believe that your partner feels positive about your relationship? 
d) Are there any major issues troubling you regarding the relationship (for example, trust issues, 
resentments)? 
e) Do you feel you can talk to your partner about these issues? 
2) Are you currently experiencing any sexual difficulties? If yes, what are they? 
3) Was there any time in your life when you experienced personal desire for sexual activity (for 
example, positive sexual thoughts/fantasies about having sexual activities)? 
4) Was there a time in your life that you were you able to become sexually aroused or excited when 
you engaged in sexual activities? 
5) Was there a time with your current partner that you had desire for sexual activity and routinely 
became aroused? 
6) Have you sometimes initiated sexual activity with your partner in the past, prior to your current 
sexual problems? 
INSTRUCTIONS: This guide is designed to facilitate the diagnostic assignment of possible cases of 
female sexual dysfunction (FSD) into one of three categories: hypoactive sexual desire disorder 
(HSDD) (ie, HSDD Distinct); HSDD with arousal problems (ie, HSDD Mixed (HSDD/female sexual 
arousal disorder [FSAD]); or neither condition present. The questions reflect the diagnostic 
criteria in Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV and those proposed in 
DSM-5. The guide is intended as an outline for you to follow in making your diagnostic decision. 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
29
HSDD Screen: 
7) Would you say that, for at least the past 6 months, your desire for sexual activity has decreased 
compared to what it was previously? 
8) Has the number or intensity of your sexual thoughts/daydreams decreased over this time? 
9) How do you feel about this change in desire? 
a) Are you worried about this decrease? 
b) Does it distress you? 
c) Does it distress your partner? 
10) When did you first notice this decrease? Was the onset gradual or sudden? 
Screen for Comorbid Arousal Problems: 
11) During the past 6 months, when you engaged in sexual activity did you have difficulty becoming 
or staying mentally aroused or excited? 
12) How do you feel about this change? Are you concerned about this difficulty with becoming 
mentally aroused? 
13) How long have you experienced this problem with mental arousal? 
Lubrication: 
14) Would you say that, for at least the past 6 months, you have had difficulty experiencing adequate 
vaginal lubrication or other arousal difficulties during sexual activity (for example, genital 
swelling and tingling, nipple sensitivity)? 
15) How long have you experienced this problem with lubrication? 
16) How do you feel about this change? Does this problem concern you? 
Orgasmic Difficulties: 
17) During the past 6 months have you been having any problems with having orgasms? 
18) How long have you experienced this problem achieving an orgasm? 
19) Does this orgasmic problem concern you? 
Pain: 
20) Would you say that, for at least the past 6 months, you have had difficulty or problems with pain 
(either vaginally or elsewhere) during sexual activity? 
21) How long have you experienced this pain problem? 
22) Does the pain interfere with sexual activity? What impact has the pain had on your sexual life? 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
30
23) Does this pain problem concern you? 
NOTE: If there is an absence of a formal diagnosis of sexual dysfunction, skip the section below on 
Mitigating Factors. 
Mitigating Factors (SKIP THIS SECTION if there is no formal diagnosis of sexual dysfunction) 
Now let me take a few minutes to review some factors that may have contributed to your current 
sexual problems. Please let me know if you feel any of the following issues have made a significant 
contribution to your sexual difficulties. 
a.) Medical Condition: 
 
b.) Life Stress: 
 
c.) Medications: 
 
d.) Surgery: 
 
e.) Relationship Issues: 
 
 
 
 
 
 
 
Copyright © 2011 by Leonard R. Derogatis, Ph.D.

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
31
DIAGNOSIS: 
PART A: FOR ALL SUBJECTS 
Please place a check in the box below that most accurately describes the subject’s diagnostic status. 
HSDD 
without 
decreased 
arousal 
HSDD 
with 
decreased 
arousal 
No 
HSDD 
 
PART B: FOR ALL SUBJECTS WITH SEXUAL DYSFUNCTION 
Circle the appropriate choice which describes their sexual dysfunction. 
LIFELONG 
OR 
ACQUIRED 
GENERALISED 
OR 
SITUATIONAL 
PART C: SUPPLEMENTARY QUESTION 
For what percentage of your sexual encounters do you have 
absent/reduced sexual excitement/pleasure during sexual activity? (in 
identified situational contexts or, if generalised, in all contexts) 
(Write answer in box to the right or indicate NA for not applicable) 
 
NOTES:   
 
 
 
 
 
 
For how long prior to Screening has the subject had HSDD 
(with or without decreased arousal)? 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
32
DSM-5 CHECKLIST 
Female Sexual Interest and Arousal Disorder (SI/AD) – Diagnostic Criteria*  
Yes 
No 
A.  Lack of, or significantly reduced, sexual interest/arousal, as manifested by at least three of the following: 
1)   Absent/reduced interest in sexual activity. 
2)   Absent/reduced sexual/erotic thoughts or fantasies. 
3)   No/reduced initiation of sexual activity and typically unreceptive to a partner’s 
attempts to initiate. 
4)   Absent/reduced sexual excitement/pleasure during sexual activity in almost all or 
all (approximately 75% to 100%) sexual encounters (in identified situational 
contexts or, if generalised, in all contexts). 
5)   Absent/reduced sexual interest/arousal in response to any internal 
or external sexual/erotic cues (e.g., written, verbal, visual) 
6)   Absent/reduced genital or nongenital sensations during sexual activity in almost 
all or all (approximately 75% to 100%) sexual encounters (in identified situational 
contexts or, if generalised, in all contexts). 
B.   The symptoms in Criterion A have persisted for a minimum duration of approximately 
6 months. 
C.   The symptoms in Criterion A cause clinically significant distress in the individual. 
D.  The sexual dysfunction is not better explained by a nonsexual mental disorder or as a 
consequence of severe relationship distress (e.g., partner violence) or other significant 
stressors and is not attributable to the effects of a substance/medication or another 
medical condition. 
Specify whether: 
Circle the Appropriate Choice: 
1)   Lifelong: The disturbance has been present since the individual 
became sexually active 
        Acquired: The disturbance began after a period of relatively normal 
sexual function. 
Lifelong 
Acquired 
2)   Generalised: Not limited to certain types of stimulation, situations, or 
partners 
Situational: Only occurs with certain types of stimulation, situations, 
or partners 
Generalised 
Situational 
3)   Severity of distress associated with symptoms in Criterion A 
Mild 
Moderate 
Severe 
Circle 
the 
Number 
that 
Corresponds to How Relevant the 
Specifier is for the Diagnosis: 
Not 
Extremely 
R l
t
R l
t
4)   Partner factors (partner’s sexual problems, partner’s health status) 
0 
1 
2 
3 
4 
5 
5)   Relationship factors (for example, poor communication, relationship 
discord, discrepancies in desire for sexual activity) 
0 
1 
2 
3 
4 
5 
6)   Individual vulnerability factors (for example, depression or anxiety, 
poor body image, history of abuse experience) 
0 
1 
2 
3 
4 
5 
7)   Cultural/religious factors (for example, inhibitions related to 
prohibitions against sexual activity) 
0 
1 
2 
3 
4 
5 
8)   With medical factors relevant to prognosis, course, or treatment 
0 
1 
2 
3 
4 
5 
*Text in the checklist is taken from the Diagnostic and Statistical Manual of Mental Disorders – 5th Edition, DSM-5™, American Psychiatric 
Association, 2013 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
33
APPENDIX 
C: 
FEMALE 
SEXUAL 
FUNCTION 
INDEX 
(FSFI) 
QUESTIONNAIRE 
INSTRUCTIONS: These questions ask about your sexual feelings and responses during the 
past 4 weeks.  Please answer the following questions as honestly and clearly as possible. 
Your responses will be kept completely confidential. In answering these questions, the 
following definitions apply: 
 
Sexual activity can include caressing, foreplay, masturbation, and vaginal intercourse.  
 
Sexual intercourse is defined as penile penetration (entry) of the vagina. 
 
Sexual stimulation includes situations like foreplay with a partner, self-stimulation 
(masturbation), or sexual fantasy. 
 
 
CHECK ONLY ONE BOX PER QUESTION 
 
Sexual desire or interest is a feeling that includes wanting to have a sexual experience, 
feeling receptive to a partner’s sexual initiation, and thinking or fantasizing about 
having sex. 
 
1. Over the past 4 weeks, how often did you feel sexual desire or interest? 
 
 Almost always or always 
 Most times (more than half the time)  
 Sometimes (about half the time) 
 A few times (less than half the time)  
 Almost never or never 
 
2. Over the past 4 weeks, how would you rate your level (degree) of sexual desire or 
interest? 
 
 Very high 
 High 
 Moderate 
 Low 
 Very low or none at all  

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
34
Sexual arousal is a feeling that includes both physical and mental aspects of sexual 
excitement. It may include feelings of warmth or tingling in the genitals, lubrication 
(wetness), or muscle contractions. 
 
3. Over the past 4 weeks, how often did you feel sexually aroused (“turned on”) during 
sexual activity or intercourse? 
 
 No sexual activity 
 Almost always or always 
 Most times (more than half the time)  
 Sometimes (about half the time)  
 A few times (less than half the time)  
 Almost never or never 
 
4. Over the past 4 weeks, how would you rate your level of sexual arousal (“turned on”) 
during sexual activity or intercourse? 
 
 No sexual activity  
 Very high 
 High 
 Moderate  
 Low 
 Very low or none at all 
 
5. Over the past 4 weeks, how confident were you about becoming sexually aroused during 
sexual activity or intercourse? 
 
 No sexual activity 
 Very high confidence  
 High confidence  
 Moderate confidence  
 Low confidence 
 Very low or no confidence 
  
6. Over the past 4 weeks, how often have you been satisfied with your arousal (excitement) 
during sexual activity or intercourse? 
 
 No sexual activity 
 Almost always or always 
 Most times (more than half the time)  
 Sometimes (about half the time)  
 A few times (less than half the time) 
 Almost never or never 
 
 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
35
7. Over the past 4 weeks, how often did you become lubricated (“wet”) during sexual activity 
or intercourse? 
 
 No sexual activity 
 Almost always or always 
 Most times (more than half the time) 
 Sometimes (about half the time) 
 A few times (less than half the time) 
 Almost never or never 
 
8. Over the past 4 weeks, how difficult was it to become lubricated (“wet”) during sexual 
activity or intercourse? 
 
 No sexual activity 
 Extremely difficult or impossible 
 Very difficult 
 Difficult 
 Slightly difficult 
 Not difficult 
 
9. Over the past 4 weeks, how often did you maintain your lubrication (“wetness”) until 
completion of sexual activity or intercourse? 
 
 No sexual activity 
 Almost always or always 
 Most times (more than half the time)  
 Sometimes (about half the time)  
 A few times (less than half the time)  
 Almost never or never 
 
10. Over the past 4 weeks, how difficult was it to maintain your lubrication (“wetness”) until 
completion of sexual activity or intercourse? 
 
 No sexual activity 
 Extremely difficult or impossible 
 Very difficult 
 Difficult 
 Slightly difficult 
 Not difficult 
 
11. Over the past 4 weeks, when you had sexual stimulation or intercourse, how often did 
you reach orgasm (climax)? 
 No sexual activity 
 Almost always or always 
 Most times (more than half the time) 
 Sometimes (about half the time) 
 A few times (less than half the time) 
 Almost never or never 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
36
12. Over the past 4 weeks, when you had sexual stimulation or intercourse, how difficult was 
it for you to reach orgasm (climax)? 
 
 No sexual activity 
 Extremely difficult or impossible 
 Very difficult 
 Difficult 
 Slightly difficult 
 Not difficult 
 
13. Over the past 4 weeks, how satisfied were you with your ability to reach orgasm (climax) 
during sexual activity or intercourse? 
 
 No sexual activity 
 Very satisfied 
 Moderately satisfied 
 About equally satisfied and dissatisfied  
 Moderately dissatisfied  
 Very dissatisfied 
 
14. Over the past 4 weeks, how satisfied have you been with the amount of emotional closeness 
during sexual activity between you and your partner? 
 
 No sexual activity 
 Very satisfied 
 Moderately satisfied 
 About equally satisfied and dissatisfied 
 Moderately dissatisfied  
 Very dissatisfied 
 
15. Over the past 4 weeks, how satisfied have you been with your sexual relationship with 
your partner? 
 
 Very satisfied 
 Moderately satisfied 
 About equally satisfied and dissatisfied  
 Moderately dissatisfied  
 Very dissatisfied 
 
16. Over the past 4 weeks, how satisfied have you been with your overall sexual life? 
 
 Very satisfied 
 Moderately satisfied 
 About equally satisfied and dissatisfied  
 Moderately dissatisfied  
 Very dissatisfied 
 
17. Over the past 4 weeks, how often did you experience discomfort or pain during vaginal 
penetration? 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
37
 
 
 Did not attempt intercourse 
 Almost always or always 
 Most times (more than half the time)  
 Sometimes (about half the time)  
 A few times (less than half the time)  
 Almost never or never 
  
18. Over the past 4 weeks, how often did you experience discomfort or pain following 
vaginal penetration? 
 
  Did not attempt intercourse 
 Almost always or always 
 Most times (more than half the time)  
 Sometimes (about half the time) 
 A few times (less than half the time)  
 Almost never or never 
 
19. Over the past 4 weeks, how would you rate your level (degree) of discomfort or pain 
during or following vaginal penetration? 
 
 Did not attempt intercourse 
 Very high 
 High 
 Moderate 
 Low 
 Very low or none at all 
 
 
 
Thank you for completing this questionnaire. 
 
D. Ferguson and R. Rosen, 2000 
 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
38
APPENDIX D: FEMALE SEXUAL DISTRESS SCALE - 
DESIRE/AROUSAL/ORGASM (FSDS-DAO) QUESTIONNAIRE 
INSTRUCTIONS 
 
Below is a list of feelings and problems that women sometimes have concerning their sexuality. Please read 
each item carefully, and circle the number that best describes HOW OFTEN THAT PROBLEM HAS 
BOTHERED YOU OR CAUSED YOU DISTRESS DURING THE PAST 30 DAYS INCLUDING 
TODAY. Circle only one number for each item, and take care not to skip any items. If you change your 
mind, erase your first circle carefully. Read the example before beginning, and if you have any questions 
please ask about them. 
 
Example: How often did you feel: Personal responsibility for your sexual problems? 
 
NEVER 
RARELY 
OCCASIONALLY 
FREQUENTLY 
ALWAYS 
0 
1 
2 
3 
4 
  
 
 
 
HOW OFTEN DID YOU FEEL: 
 
1. Distressed about your sex life 
0 
1 
2 
3 
4 
2. Unhappy about your sexual relationship 
0 
1 
2 
3 
4 
3. Guilty about sexual difficulties 
0 
1 
2 
3 
4 
4. Frustrated by your sexual problems 
0 
1 
2 
3 
4 
5. Stressed about sex 
 
0 
1 
2 
3 
4 
6. Inferior because of sexual problems 
0 
1 
2 
3 
4 
7. Worried about sex 
0 
1 
2 
3 
4 
8. Sexually inadequate 
0 
1 
2 
3 
4 
9. Regrets about your sexual functioning 
 
0 
1 
2 
3 
4 
10. Embarrassed about sexual problems 
0 
1 
2 
3 
4 
11. Dissatisfied with your sex life 
0 
1 
2 
3 
4 
12. Angry about your sex life 
0 
1 
2 
3 
4 
13. Bothered by low sexual desire 
0 
1 
2 
3 
4 
14. Concerned by difficulties with sexual arousal 
 
0 
1 
2 
3 
4 
15. Frustrated by problems with orgasm 
0 
1 
2 
3 
4 
 
 
 
 
 
Copyright © 2011 by Leonard R. DeRogatis, Ph.D. 
 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
39
APPENDIX E: Visual Analogue Scale  
 
Please place a vertical mark along the line according to how you are feeling 
Example:  
 
How hungry do you feel right now? 
  NOT AT ALL  
 
 
 
 
 
 
                       EXTREMELY 
 
How sick (or nauseous) do you feel right now? 
  NOT AT ALL  
 
 
 
 
 
 
 
          EXTREMELY 
 
How pleasant would it be to eat right now? 
  NOT AT ALL  
 
 
 
 
 
 
 
          EXTREMELY 
 
How much do you think you could eat right now? 
   NOTHING  
 
 
 
 
 
 
                       A LARGE 
AMOUNT                                  
                                                                                         
 
 
 
How full do you feel right now? 
  NOT AT ALL  
 
 
 
 
 
 
 
          EXTREMELY 
 
How sleepy do you feel right now? 
  NOT AT ALL  
 
 
 
 
 
 
                       EXTREMELY 
 
 
 
 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
40
APPENDIX F: State-Trait Anxiety Inventory Y-1 and Y-2 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
41
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
42
APPENDIX G: The Sexual Arousal and Desire Inventory (SADI) 
Sexual Arousal is defined as the physiological responses that accompany or follow sexual desire. For 
example, when you feel sexually aroused, your heart might beat faster or your palms may get sweaty. 
Men may experience penile erection, and women may feel a moistness of the vagina. Sexual Arousal 
involves the more physiological aspects of wanting sex. Sexual desire is defined as an energizing force 
that motivates a person to seek out or initiate sexual contact and behaviour. You can think of it as a 
hunger or a sexual ‘drive’ that leads you to seek out sexual contact. Sexual desire involves the more 
psychological aspects of wanting sex.  
Keep in mind the definitions of sexual arousal and sexual desire. Following is a list of words that might 
describe how you feel currently.  Different people experience sexual arousal and desire in distinct, 
individual ways. There is no ‘right’ or ‘wrong’ answer. Please indicate to what extent each word 
describes how you feel RIGHT NOW, by placing the number that describes the feeling most accurately. 
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
43
APPENDIX H: The Positive and Negative Affect Schedule (PANAS)  

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
44
APPENDIX I: D2 Test of Attention 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
45
 

Version number: 5 
 
IRAS project ID: 262886 
                Date: 24th January 2020 
 
 
 
 
 
46
APPENDIX J: Follow-up Questionnaire  
 
1. Did you feel an increase in sexual desire after administration of study drug? YES/NO 
 
2. If yes, how long after study drug administration did the increase in sexual desire last? 
 
0-2 hrs 
>2-4 hrs 
>4-8 hrs 
>8-12 hrs 
>12-18 hrs 
>18-24 hrs 
 
 
Thank you